GILD

Business Context and Reporting Period

Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1998
Business Overview: Gilead is a biopharmaceutical company focused on research and development (R&D) of therapeutic drug candidates. The company markets VISTIDE (cidofovir injection) in the U.S. for the treatment of CMV retinitis in AIDS patients, with Pharmacia & Upjohn holding exclusive rights outside the U.S. The company has incurred losses in every quarter since inception, except for two quarters in 1996 and 1997 driven by collaboration milestones.

Key Financial Metrics

Note: Q2 Operating Cash Flow is not explicitly broken out in the source text; only the six-month figure is provided.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues dropped significantly from $19.7 million in Q2 1997 to $7.0 million in Q2 1998. This is primarily due to the absence of one-time milestone payments received in 1997 (a $10 million payment from Pharmacia & Upjohn and a $3 million payment from Roche) and a decline in VISTIDE product sales.
• Increased Expenses:
  • R&D Expenses: Increased 24.5% in Q2 1998 ($18.3 million) compared to Q2 1997 ($14.7 million), driven by advancing four therapeutic candidates into later clinical stages.
  • SG&A Expenses: Increased 37.7% in Q2 1998 ($8.4 million) compared to Q2 1997 ($6.1 million), reflecting support for increased R&D activities.
• Net Loss Widening: The company swung from a net income of $2.7 million in Q2 1997 to a net loss of $14.8 million in Q2 1998. For the six-month period, the loss widened from $5.2 million in 1997 to $22.2 million in 1998.
• Contract Revenues: While total contract revenues decreased due to the lack of 1997 milestones, the company received $14.6 million from Roche in the first six months of 1998 as reimbursement for development expenses related to GS 4104.

Guidance, Outlook, and Risks

• Profitability Outlook: Management expects to incur losses throughout 1998 and 1999 due to ongoing R&D programs, clinical trials, and marketing efforts for VISTIDE and other candidates.
• Expense Forecast: R&D and SG&A expenses are expected to increase significantly in the remainder of 1998 compared to 1997 levels, driven by clinical trials for several product candidates and the anticipated launch of PREVEON (an investigational HIV drug).
• Liquidity: The company holds approximately $312.6 million in cash and short-term investments. Management believes existing resources, supplemented by revenues, are adequate for the foreseeable future, though future funding may be required via equity, debt, or collaborations.
• Key Risks:
  • Uncertainty in clinical trial results and regulatory approvals.
  • Declining market for VISTIDE due to more effective HIV therapies reducing the incidence of CMV retinitis.
  • Intense competition and pricing pressure from payors.
  • Year 2000 compliance issues, though management expects costs to be insignificant and systems to be updated by December 31, 1998.

Investor Verification Checklist

• Revenue Sustainability: Verify the extent to which future revenues rely on one-time milestone payments versus recurring product sales, given the significant drop in 1998 revenues.
• Burn Rate: Confirm the trajectory of R&D and SG&A spending increases and their impact on the company's cash runway.
• VISTIDE Market Dynamics: Assess the long-term viability of VISTIDE sales as HIV therapies improve and reduce the target patient population.
• Clinical Pipeline Progress: Monitor the status of the four therapeutic candidates advancing to later clinical stages to validate the increased R&D spend.
• Collaboration Terms: Review the terms of the Roche and Glaxo Wellcome agreements, noting the termination of the Glaxo Wellcome code blocker program in June 1998.